New treatment for women who experience sexual arousal problems following the menopause
Research status
Completed
Overview of Study
A Randomised, Double-Blind, Placebo-Controlled, Parallel group, Multicentre, 24-week Study to Evaluate the Efficacy and Safety of Transdermal Testosterone (300 mcg/day) in Naturally Menopausal Women with Hypoactive Sexual Desire Disorder Receiving Systemic Transdermal Oestrogen, Oral Non-Conjugated Equine Oestrogen, or No Oestrogen Therapy
Objectives of study
The aim of this study was to examine the safety and effectiveness of an investigational testosterone patch treatment in women who experienced low sex drive after going through the menopause.
- had noticed a loss of libido which caused them personal distress
- were aged between 40 and 70 years of age
- were in an established relationship of at least 6 months
- had not had a period for 1 year
- were using any form of HRT
Subjects were assigned randomly to either a transdermal skin patch releasing 300 mcg testosterone daily or a placebo patch for 24 weeks. The subjects attended four visits and completed questionnaires on sexual satisfaction weekly and more detailed depression and sexual function assessments at randomisation and weeks 12 and 24 of patch use.
